Csenge Advisory Group
BIB icon

Csenge Advisory Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Csenge Advisory Group’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,856
Closed -$233K – 770
2026
Q1 		$233K Buy
+2,856
New +$237K 0.01% 660

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Capital Investment Advisors
Capital Investment Advisors Atlanta, Georgia $7.59B AUM 23.38% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $254M AUM 28.38% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $478M AUM 50.95% 1-Year Est. Return
Jump Financial
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $474M AUM 95.11% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Ashton Thomas Private Wealth
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

Csenge Advisory Group's BIB Position: Q2 2026 in Review

Csenge Advisory Group sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2026, closing a stake of 2,856 shares — an estimated $233K sold.

Csenge Advisory Group first reported a position in BIB in Q1 2026 and held it in 1 quarter. The position peaked at $233K in Q1 2026. 20 funds tracked by Wall St. Rank hold BIB as of Q2 2026.

  • Csenge Advisory Group reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Csenge Advisory Group sold 2,856 ProShares Ultra NASDAQ Biotechnology shares in Q2 2026, an estimated $233K.
  • Csenge Advisory Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2026 and held it in 1 quarter.
  • Csenge Advisory Group's ProShares Ultra NASDAQ Biotechnology position peaked at $233K in Q1 2026.
  • 20 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2026.

Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.